Lexicon Appoints Ivan H. Cheung to Board of Directors
November 20, 2024 16:05 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Ivan H. Cheung has been elected to its Board of Directors. Mr. Cheung is...
Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association’s (AHA) Sessions 2024 in Chicago
November 14, 2024 08:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from four studies of sotagliflozin will be delivered during the...
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024 16:05 ET
|
Lexicon Pharmaceuticals, Inc.
Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe Completed ZYNQUISTA™ FDA Advisory Committee Meeting; PDUFA Goal Date December 20,...
Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference
November 06, 2024 08:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies London Global Healthcare Conference. Lexicon...
Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease
November 05, 2024 16:05 ET
|
Lexicon Pharmaceuticals, Inc.
People with T1D and CKD treated with sotagliflozin and insulin had similar lowering effects on glycated hemoglobin (HbA1c), the primary endpoint, as people with T1D who do not have CKD Sotagliflozin...
Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024
November 05, 2024 08:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its third quarter 2024 financial results on Tuesday, November 12, 2024 after the...
Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss
November 04, 2024 08:00 ET
|
Lexicon Pharmaceuticals, Inc.
Investigational New Drug (IND) application planned in 2025 for LX9851, a first-in-class, potent, selective, orally bioavailable molecule, as an anti-obesity agent Data from Lexicon’s Obesity Week...
Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease
October 31, 2024 18:54 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the outcome of the U.S. Food and Drug Administration (FDA) Endocrinologic and...
New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024
October 23, 2024 09:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a new analysis of its Phase 3 SCORED clinical trial demonstrating the protective...
Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
October 22, 2024 08:00 ET
|
Lexicon Pharmaceuticals, Inc.
Top-line Data Now Anticipated in Q1 2025 LX9211 has previously received Fast Track designation from the U.S. Food and Drug Administration (FDA) for DPNP THE WOODLANDS, Texas, Oct. 22, 2024 ...